Abstract 42P
Background
The study investigates the potential of OZ-001, a novel 3,4-dihydroquinazoline derivative containing a ureido group, against diverse cancers. Conventional chemotherapy has limited impact on triple-negative breast cancer (TNBC), and targeted TNBC therapies are lacking. OZ-001 is expected to target both signal transducer and activator of transcription 3 (STAT3) inhibition and T-type calcium channel blocking simultaneously.
Methods
The efficacy and potency of OZ-001 were assessed using MDA-MB-231 cells both in vitro and in vivo. Cell-based assays compassing cell viability, apoptosis, protein expression, cell cycle analysis, fluorescence polarization assay (FP), and intracellular calcium levels were conducted. An in vivo xenograft model using MB-231 cells gauged impact of OZ-001 via oral administration (ranging from 15 to 60mg/kg). Preliminary toxicity evaluation of OZ-001 was conducted using an in vivo model with RD rats.
Results
In vitro, OZ-001 displayed substantial does-dependent inhibition of cell viability inducing a remarkable 10-fold increase in apoptotic genes Bax and caspase-3 compared to the control. As a STAT3 inhibitor, OZ-001 effectively disrupted STAT3-STAT3 interactions in the FP assay, and it reduce STAT3 phosphorylation by 90%. As a T-type calcium channel blocker, OZ-001 exhibited the capability to reduce intracellular calcium levels by 50%, resulting in a notable 90% reduction in calcium signaling. In vivo, OZ-001 led to a 50% reduction in tumor size at a dose of 15mg/kg, and an impressive 95% at 60mg/kg (P.O.), compared to the vehicle-treated group, while a 70% reduction in tumor size at a dose of 10 mg/kg (IP) of Paclitaxel was observed. In a single oral dose toxicity evaluation using SD rats, no specific clinical sign or distinctive necropsy findings were observed, even at a dose of 2,000 mg/kg of OZ-001. This indicates its favorable safety profile.
Conclusions
OZ-001 emerges as a promising therapeutic candidate for TNBC, demonstrating exceptional efficacy as an orally active single agent in reducing tumor growth. The preclinical results present an encouraging avenue for further exploration and development of OZ-001 as a viable alternative for addressing TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ONCOZEN Co., Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract